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A b s t r a c t  
Paclitaxel (PTX) is an anticancer drug belonging to the class of Taxan. It is active against various 
types of carcinomas. The marketed formulation of paclitaxel is associated with deleterious effects 
with lack of specificity to tumor. Solid lipid nanoparticles (SLN) are colloidal carriers extensively 
studied and developed for their potential uses especially for controlled release and site specificity. 
The present study was designed to develop a formulation of PTX in the form of SLN to be 
administered via IV route with improved tumor specificity, in which the lipid shell was modified by 
using combination of lipid with phospholipids. Total eight formulations were prepared and were 
characterized by various in vitro and in vivo parameters. The microemulsification method was used 
for the preparation of SLN. The production yield  of resulting process for all SLN was high. Average 
particle size was ranged between 209 nm to 385 nm. The developed PTX-SLN showed high 
percentage entrapment efficiency. The zeta potential values showed the good stable feature of the 
SLN. The in vitro dissolution study showed that drug release was more retarded and was found to 
dependent on concentration of lipids employed. In vitro cytotoxicity study was performed on MCF-7 
cancer cell line, which showed that formulation G2 is having more potentiating effect on cancer cell 
line. Tissue targeting study and tumor growth inhibition studies were performed on mice where the 
PTX loaded SLN from batch G2 shown more promising outcome. Results obtained from this study 
indicated strongly that developed SLN are having potential as an efficient drug delivery system for 
paclitaxel.  
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Introduction 
Cancer occurs due to abnormal cell growth, because of cell 
division without any control, which is an altered functionality of the 
cells[1]. Chemotherapy is the treatment of cancer with drugs 
(anticancer drugs) that can destroy cancer cells.[2].  
Paclitaxel (PTX) is an taxane, derived from Pacific Yew tree and is 
active against various cancers.PTX is one of the several 
cytoskeletal drugs that target tubulin. PTX-treated cells have 
defects in mitotic spindle assembly, chromosome segregation, and 
cell division. PTX stabilizes the microtubule polymer and protects it 
from disassembly. This blocks progression of mitosis, and 
prolonged activation of the mitotic checkpoint triggers apoptosis or 
reversion to the G-phase of the cell cycle without cell division. [3,4]  
The use of PTX is having its potential advantages as it can cure 
the cancer but have some drawbacks. The conventional 
formulation of PTX is in the form of IV solution, formulated with 
Cremophor EL and Ethanol, marketed as Taxol. This formulation 
often results in anaphylactic reaction in patients ultimately 
questioning the therapeutic benefits of PTX. The harmful effects of 
this drug are seen as they are distributed in cancer cell as well in 
healthy tissues. The drawbacks of this treatment are due to lack of 
specificity of cytotoxic agents to cancer cells [5].  
An ideal drug delivery system should result maximum therapeutic 
benefits of drug, which should include the safe and effective 
management of disease, and it should improve patient compliance 
[6]. 
Cancer therapy with chemotherapeutic agents is undergoing a 
constant improvisation cycle. This is much needed to meet the 
current demands of disease. The main research is seen with 
respect to finding new drug delivery systems and constant up 
gradation of existing ones. In this regard, much focus is given to 
carriers with site specificity [7].  
For the purpose of tissue targeting various moieties were taken on 
radar namely microparticles [8]. Microballons [9]. bioresponsive 
systems[10]. colloidal carriers[11]. etc. 
The scientists have always given their preference to these carriers 
as they are having tremendous potential in present drug 
formulation industry. These carriers are studied extensively and 
have been produced on large scale because these are the one, 
which meets the current demand of therapy.  
Out of these, colloidal carriers have gained attention of 
pharmaceutical scientists, as these are associated with an 
advantage of site specificity and optimal drug release profile. 
These are the characteristics, which are very important one, as 
appropriate measure of disease treating is concern. [12].  
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The nanotech components are very useful findings from the 
viewpoint of drug delivery system that will hopefully carry 
therapeutic and diagnostic agents to specific sites in the body 
allowing for highly targeted treatments that could minimize side 
effects. [13].  
To meet above stated goals of drug delivery system solid lipid 
nanoparticles have shown great potential. Solid lipid nanoparticles 
are a novel nano particulate system, which is attracting major 
attention as an alternative colloidal carrier system to polymeric 
nanoparticles, liposomeÊs and nanoemulsion [14-17]. 
These carriers have advantages like improved stability of drugs, 
encapsulation of agents of diversified physicochemical properties, 
enhanced drug efficacy, improved pharmacokinetics and less 
toxicity. They have been reported as useful drug carriers [18-20].  
Extensive researches have been done on solid lipid nanoparticles 
of several chemotherapeutic agents in suitable carriers and their in-
vitro and in-vivo efficacy have been evaluated.  
However the formulation of SLN by mixed lipid blend and itÊs in 
vitro and in vivo biodistribution has not been previously reported. 
There potential for efficiency of site specificity is not studied. 
Therefore present study was undertaken to develop PTX loaded 
SLN designed by lipid shell modified with lipid and phospholipids 
blend as to study its in vitro characteristics and in vivo 
biodistribution studies in tumor bearing mice. 
Materials  
Paclitaxel (IP grade) was supplied by Unan Hande Biotech Co. Ltd. 
China, Stearic acid was purchased S.D. Fine Chemicals, Mumbai, 
Di-palmitoyelphosphotidylcholine (DpPC) and 1,2 Dipalmitoyel SN 
Glycero 3- Phospho Glycerol, Sodium (DPPG,Na) were procured 
from Genzyme, Switzerland. Sodium glycholate and Soya lecithin 
were purchased from Across Organics, New Jersey, USA. 
Potassium dihydrogen phosphate was procured from Ranbaxy 
Fine Chemicals New Delhi. Ethanol and other solvents were 
purchased from local suppliers. All the chemicals were used as 
supplied , without further purification. 
Table 1 Formulation Table Design for SLN Prepared by using 
Combination of 3 Lipids 
Form. 
code 
Drug 
(Parts) 
Soy 
Lecithi
n (%) 
Sodium 
Tauroc
holate 
(%) 
Stearic 
Acid 
(Parts) 
DpP
C 
(Par
ts) 
DPPG
.Na 
(Parts) 
G1 1 15 0.8  10  10 10
G2 1 15 0.8   5    5   5
G3 1 15 0.8 10  10   5
G4 1 15 0.8  10    5 10
G5 1 15 0.8    5  10 10
G6 1 15 0.8   5    5 10
G7 1 15 0.8    5  10   5
G8 1 15 0.8  10    5   5
 
Preparation of Paclitaxel Loaded Solid Lipid 
Nanoparticle  
Total 8 batches of PTX loaded SLN were prepared. The 
formulation table no.1 shows the concentration of various 
ingredients for preparation of PTX- SLN. 
Solid lipid nanoparticles of PTX were prepared by micro 
emulsification technique using soy lecithin as surfactant, sodium 
glycholate as co surfactant and 0.1 N Hcl as liquid manufacturing 
vehicle. Shell material was melted at a temperature of 800c to the 
melted shell constituent PTX drug was added with 5 min. stirring 
followed by sonication [21]. 
To this mixture soy lecithin was added and stirred for 2 minutes. 
Aqueous phase containing co surfactant sodium glycholate was 
heated at 80o.c and added to melted shell phase mechanical 
stirring at 800c for 10-15 minutes, formed o/w microemulsion.  The 
micro emulsion was carefully added drop wise into ice cold water in 
a beaker with continuous stirring a 5 cc glass syringe fitted with 21 
gauge needle was used to control the particle size. 
The mixture was stirred at 3000rpm and SLN dispersion was stirred 
for three hrs after complete addition of microemulsion. The SLN 
dispersion was subjected to ultrasonication for 10 minutes. 
Collected formulations were lyophilized to get free flowing product. 
Particle Size Analysis  
The size of particle is an important parameter for SLN to be 
administered via parentral route. The particle size is crucial for 
controlled drug release and tissue specificity of drug. Particle size 
less 100 nm are rapidly taken up in RES and there specificity less  
So in present study due concern is given to the particle size in the 
range of 200 nm to 250 nm. The particle size of developed SLN 
was determined by  Dynamic Light Scattering Particle Size 
Analyzer (Nanotrac Particle Size Analyzer) [22]. 
Percentage Yield  
To check process capability to produce drug loaded SLN 
percentage practical yield was determined. This assures the output 
obtained after the completion of production operation. The 
lyophilized PTX-SLN from each formulation were weighed and the 
respective percentage yield was calculated using the formula no. 
[1] [23]. 
Percentage Yield=(Wt of SLN obtained / Wt of drug +polymers 
used) X 100            ⁄ [1] 
Determination of Entrapment Efficiency Percentage  
The amount of drug equivalent to one dose from SLN is calculated 
based on % EE. It is desirable to have high EE as it will allows  
less quantity of sln/ unit dose of drug, in comparison to low EE 
which will need more quantity of SLN/unit dose of drug [24]. 
Entrapment efficiency of PTX loaded SLN was estimated by 
centrifugation method. The prepared SLN were placed in 
centrifugation tube and centrifuged at 15000 rpm for 30 min. The 
supernatant (1ml) was withdrawn and diluted with methanol. The 
unentrapped PTX was determined by UV spectrophotometer at 
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227 nm. The samples from the supernatant were diluted suitably 
before going for absorbance measurement. The free PTX in the 
supernatant gives the total amount of unentrapped drug. 
Encapsulation efficiency is expressed as the percent of drug 
entrapped and was calculated using equation no. [2]. 
 
% E.E. = {(Total amount of drug ă Free dissolved drug) / Total 
amount of drug} X 100 ⁄..[2]. 
SEM Study  
Surface topography gives about external feature of prepared 
formulations. Scanning electron microscopy was done to study the 
particle surface morphology and shape. SEM was done by using 
JSM-T330A, JEOL, Hindal, India. 
Zeta Potential Determination  
Zeta potential was measured by using Zetatrac. Sample was filled 
into the cell; electrodes are inserted, placed under the microscope, 
and connected them to the Zeta-Meter 3.0+ unit.  All data were 
taken in triplicate [25]. 
In Vitro Release Study  
The release of PTX from the nanoparticles was measured in 
triplicate in PBS (PH 7.4). SLN equivalent to 10 mg of PTX were 
placed in dialysis bag soaked overnight with dissolution fluid. 
Dialysis bag containing formulation was suspended in 200 ml of 
PBS (PH 7.4) solution in a capped beaker and placed in an orbital 
shaker, which was maintained at 370 centigrade degree and 
shaken horizontally at 120 min-1. The temperature of buffer is 
maintained at 37μ1 0c.,  release medium was withdrawn at time 
intervals of 0.5,1, 2, 4, 8, 16, 24, and 48 hrs and replaced by the 
same volume of PBS [26].  
The sample was diluted appropriately with methanol and estimated 
by     UV-Visible spectrophotometer at 227 nm. 
In-Vitro Cytotoxicity Study 
In vitro cytotoxicity of prepared SLN was done by using Breast 
cancer cell line (MCF-7 cell line).The drug, formulated in the SLN 
with the drug concentration ranging from 0.25 to 25μg/ml was used 
[27,28]. 
To perform in-vitro cytotoxicity study trypan blue dye test was used. 
Trypan Blue dye is not permeable in live cells due to the presence 
of plasma membrane. When the cells are, dead cells take up the 
dye and appear as blue colour. The method is an index of the dead 
cells in a cell population. 
Cell concentration was diluted to 1x 106 cells/ml using phosphate 
buffered saline (pH 7.4). Trypan blue dye (0.4%) was prepared in 
PBS pH 7.4 and 0.1ml of breast cancer cell line was mixed. To this 
formulation with highest particle size, and with lowest particle size 
were added. Marketed formulation of PTX (Taxol) was also 
subjected for study. 
All the samples were diluted with phosphate buffered saline (pH 
7.4) to make various concentrations of PTX in the range of 0.25 to 
25 mcg/ml, were added and incubated for 24 hours in incubator at 
370C. After this, the mixture was added with 0.1ml of trypan blue 
dye and incubated for 5 minutes at 370C. Blue colored dead cells 
and unstained viable cells were counted by using a Neubauer 
chamber using low power objective. Percentage of dead cells were 
calculated and recorded. The percentage viability and % dead cells 
were calculated by the using formula [3] and [4], 
 
                                Viable cell 
               %viability=                                                     x 100 ⁄..[3]. 
                                (Viable cell + Dead cell) 
              %Dead Cells  =100-%of viable cells              ⁄..[4]. 
In-Vivo Studies 
These studies were carried out after obtaining the due permission 
for conducting experiments from institutional ethics committee 
which is registered for „Teaching and Research on Animals‰. 
Tissue Targeting Study  
To perform tissue targeting studies, female Swiss Albino mice 
(weighing 25-30 Gms) were divided in 3 groups six in each group. 
Each mouse was inoculated with Ehlrich Ascites Carcinoma cell 
line. To perform inoculation cancer cells at a number of 1 to 2ï106 
were suspended in 0.2mL of culture medium (DMEM) and 
subcutaneously inoculated at the right thigh of each mouse using a 
1.0mL syringe. Animals were kept in a SPF facility and had free 
access to food and water [29,30]. 
After the inoculation, tumor allowed to attain volume of 100-200 
mm3.Selected formulations (G1 and G2) were administered to mice 
in two groups and third group was administered with 
Taxol(marketed formulation of PTX) at a dose of 7.5 mg per kg 
after redispersing into phosphate saline buffer pH 7.4. At 
predetermined time points (1, 4, 8, 16 and 24h), six animals from 
each group were given anesthesia and blood was collected via 
cardiac puncture. Then animals were euthanized by cervical 
dislocation and dissected. Tissues of interest (liver, kidney, hear, 
lungs, etc) were collected at different time points. Plasma and 
tissue samples were frozen at -20oC until analysis. 
Tissue samples of mice were homogenized in tissue homogenizer 
by adding 10 time volumes of distilled water containing 4% bovine 
serum albumin for 5 minute. The supernant was collected and was 
spiked with 50microlitre of internal standard methanolic solution of 
carbamazepine (5mcg/ml).The sample was then extracted twice 
with 2ml ethyl acetate. The ethyl acetate fractions were combined 
and were dried. Dried residue was dissolved in 100 microlitre of 
zinc sulphate solution, centrifuged and supernant was collected. 
Collected supernant was injected in HPLC using water: acetonitrille 
(60:40) as mobile phase. 
Tumor Growth Inhibition Studies  
To study in vivo anti tumor activity, female Swiss Albino mice were 
selected weighing 25-30 gms. Mice were divided in 4 groups, six in 
each group [31]. 
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The, Ehlrich Ascites Carcinoma cell line in its exponential growth 
was inoculated into each mouse. Cancer cells at a number of 2 to 
4ï106 were suspended in 0.2mL of culture medium and 
subcutaneously inoculated at the right thigh of each mouse using a 
1.0mL syringe. Animals were kept in a SPF facility and had free 
access to food and water.  
When the tumor volume became about 25-50 mm3, selected 
formulations (G1 and G2) were administered to mice in respective 
two groups and third group was administered with Taxol. The dose 
of total 7.5 mg/kg, three times at days 0, 4 and 8 (total 22.5 mg/kg), 
after redespersing into phosphate saline buffer pH 7.4 (1.5 mg/mL 
of PTX). 
Group 4 was maintained as untreated control group with normal 
saline.  
The tumor volumes of mice were monitored twice a week for up to 
30 days. The tumor volume calculation was performed using the 
formula,  
                                  Tumor Volume=0.4 (aïb2)        ⁄..[5]. 
Where, a  is the largest and b is the smallest diameter. 
 
Result and Discussion 
Percentage Yield  
Total percentage yield of all formulations were nearly uniform. 
Percentage yield was high in formulation G1.The results of percent 
practical yield are shown in Table 2. It increases with increase in 
concentration of lipid added to the formulation.  
Particle Size Analysis  
Dynamic Light Scattering Particle Size Analyzer measured the size 
distributions along with the volume mean diameter of the 
nanoparticles. As the total lipid concentration was raised they 
showed is an increase in average particle size (formulation G1). 
The average particle sizes of all six formulations were listed in 
Table 2. 
Determination of Entrapment Efficiency Percentage  
The results of entrapment efficiency were found to be excellent and 
were high for the formulations, which were prepared with high 
concentration combination of lipid with phospholipid. High lipid 
concentration resulted in maximum drug entrapment in formulation 
G1. The data is given in Table 2. 
Zeta Potential 
The stability study of the nanoparticle was evaluated by measuring 
the zeta potential of the SLN by the zeta meter. The G1shown high 
zeta potential value. The high zeta potential value indicate better 
stability of product as particles continue to repel each other and 
remain non aggregated. The results are tabulated in Table no. 2.  
 
Table 2 Characterization of Paclitaxel SLN Percentage Practical Yield, Particle Size, % Entrapment Efficiency, Zeta Potential and CDR after 48 
Hrs of Formulations 
Form. 
Code 
% Percentage yield Particle size 
(nm) 
% Entrapment 
Efficiency 
Zeta 
Potential(mV) 
CDR After 48 
hrs 
G1 93.16μ1.15 385.0+4.0 93+2.0 -28.58μ0.044 5.844μ2.12 
G2 93.26μ3.25 209.0+2.4 86+2.0 -24.65μ0.040 7.993μ2.10 
G3 92.93μ2.48 320.0+1.0 90+3.0 -26.88μ0.031 6.950μ2.56 
G4 93.26μ3.60 334.0+2.0 91+2.0 -25.84μ0.028 6.170μ2.68 
G5 92.77μ2.60 342.0+1.0 92+3.0 -26.48μ0.024 5.976μ2.32 
G6 92.19μ2.80 272.0+1.0 86+1.0 -23.64μ0.041 7.468μ3.20 
G7 91.37μ3.20 276.0+2.0 86+4.0 -23.72μ0.048 7.225μ3.33 
G8 91.37μ1.60 284.0+3.0 87+1.0 -24.08μ0.016 7.423μ1.20 
Each value represents mean μ S.D.  (n=3) 
 
Surface Morphology 
Scanning Electron Microscopy (JSM-T330A, JEOL) did shape and 
surface morphology of nanoparticles. SEM photograph of selected 
formulation G2 is shown in Figure 1. The PTX SLN has shown 
smooth surface and spherical shape. 
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Figure 1 Scanning Electron Microscopy study SEM Formulation G2 
 
 In Vitro Drug Release Studies 
 In vitro drug release from the SLN in phosphate buffer pH 7.4 was 
performed using dialysis bag diffusion technique. The in vitro drug 
release profile of SLN formulations obtained from dialysis 
experiment is shown in graph no. 1. It was observed that the drug 
release from the formulations slightly increases as the particle size 
of the formulation decreases and all the eight formulations showed 
a biphasic release with initial fast release. The mechanism for the 
burst release may be attributed to the drug adsorbed on SLN or 
due to leakage of drug from SLN.  
The drug release found to be dependent on the concentration of 
shell material employed. Nanoparticles prepared with high 
concentration of stearic acid, DpPC and DPPG,na showed 58.44% 
(G1) release. When lipid concentration was at low values, release 
was reported as 79.93% (G2 after 48 hours).  
The results indicated that at high concentration of shell material 
there is retardation of drug release in comparison to low 
concentration of shell material.  
Release mechanism model was chosen, based on goodness of fit 
test. Based on the highest regression values (r), the bestăfit model 
for all six formulations was Higuchi Model. PeppaÊs model with Ân ~ 
0.5Êvalue indicating non-fickian diffusion release. Thus showing 
release of PTX was found to follow HiguchiÊs classical diffusion 
model and diffusion was non-Fickian 
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Figure 2: %CDR Vs Time Plots for formulation G1-G8 
In vitro Cytotoxicity Study 
 
Two formulations (G1) and (G2) were selected for this test. 
(Formulations with high particle size and low particle size) and 
were compared with Taxol, marketed formulation of PTX. The 
results are depicted in figure. no.3 
 
Figure 3: In Vitro Cytotoxicity study.Graph of % Cell death Vs 
Paclitaxel Concentration from Formulations G1, G2 and Taxol 
 
Data indicates a significant reduction in MCF-7 cell viability 
observed when the cells were exposed to the Formulation G2, in 
comparison with SLN formulation G1. The cytotoxicity of marketed 
product, Taxol was also recorded. It was found that formulations 
G2 have shown nearly same cell cytotoxicity in comparison to 
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Taxol. The enhancement of cytotoxicy in G2 was is in accordance 
with its in vitro release profile while formulation G1 released fewer 
drugs for cell toxicity. Activity of PTX formulated in the 
nanoparticles prepared with low concentration of shell material can 
be justified by that the tumor cells can internalize the drug-loaded 
nanoparticles, allowing the drug to be released inside the cells. 
When lipid shell concentration was high resulted in high particle 
size with more difficulty to internalize into cells. 
In vivo Tissue Targeting Studies 
Formulation G1 and G2 were selected for this study along with 
Taxol. Female Swiss albino mice weighing 25-30 gm were selected 
for this study. Mice were inoculated with EAC and after growth of 
tumor to size of 100-200 mm3, mice were injected with selected 
SLN formulations of PTX and marketed formulation Taxol (7.5 
mg/kg as PTX) intravenously via tail vein of all mice. Tissues were 
collected by sacrificing the mice at 1, 4,8,16 and 24 hours of drug 
administration. Biodistribution of drug from formulation G2 were 
found to be excellent. This has shown more accumulation of drug 
in tumor tissue as compared with formulation G1 and Taxol. The 
particle size criteria was found to be crucial the SLN with smallest 
particle size shown more inhibition of tumor growth. The release of 
drug from formulation G1 was not significant in comparison to 
formulation G2, which may be due to less amount of drug released 
from the formulation. The results are indicated in figure.no.,4,5,6 ,7 
and 8. 
Analysis of plasma samples at different time points showed that 
drug is rapidly untaken and eliminated for marketed product Taxol. 
In case prepared SLN they showed presence of drug in plasma up 
to 24 hours. The biodistribution of drug from formulation G2 was 
found to be more promising, as they showed maximum drug 
concentration in tumor tissue when compared with G1 formulation 
and Taxol.  
 
 
 
Figure 4: In Vivo Tissue Targeting study Graph of Drug Conc. in mcg/gm of Organ Vs Organ from Formulations G1, G2 and Taxol after 1 
hour 
 
 
 
Figure 5: In Vivo Tissue Targeting studyGraph of Drug Conc. in mcg/gm of Organ Vs Organ from Formulations G1, G2 and Taxol after 4 
hour 
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Statistical Analysis 
The results were subjected to Dunnettes Multiple Comparison test. 
The statistical results for formulation in comparison to Taxol was 
found to very significant for all the in vivo studies (p<0.05). 
Conclusion 
The present study shown high promise as per the set objectives. 
The formulation were prepared by combination of stearic acid  and 
phospholipids DpPC and DPPG,Na..The fabricated SLN were 
subjected to characterization by various in vitro and in vivo 
methods. The SLN fabricated in present study were shown to 
perform in better way in comparison to marketed formulation of 
PTX,  
Developed SLN was shown sustained drug release that further 
advantageous in chemotherapy. The combination of lipid with 
phospholipids shown better performance in terms of there in vitro 
and in vivo characteristics. Formulation prepared with combination 
of lipid with phospholipids showed excellent in-vitro cytotoxicity 
study ,tissue targeting efficiency and  in vivo tumor growth 
inhibition studies suggesting there suitability for tumor targeting. 
Our preliminary research findings strengthened the need of 
developing colloidal carrier in the form of SLN for PTX. This will be 
very useful in improving the therapeutic performance of PTX. 
Results obtained from this study indicated strongly that developed 
SLN are having potential as an efficient drug delivery system. 
However it is recommended and convincing, to carry out more in-
vivo experimentation to support present evidence of feasibility prior 
to their clinical application 
 
.  
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